US 12,065,426 B2
Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
Ram Thaimattam, Hyderabad (IN); Suresh Babu Radhakrishnan, Hyderabad (IN); Nageswara Rao Regandla, Hyderabad (IN); Venkata Lakshmi Narasimha Rao Dammalapati, Hyderabad (IN); and Uma Maheswer Rao Vasireddi, Hyderabad (IN)
Assigned to LAURUS LABS LIMITED, Hyderabad (IN)
Appl. No. 17/283,410
Filed by Laurus Labs Limited, Hyderabad (IN)
PCT Filed Nov. 5, 2019, PCT No. PCT/IB2019/059469
§ 371(c)(1), (2) Date Apr. 7, 2021,
PCT Pub. No. WO2020/095187, PCT Pub. Date May 14, 2020.
Claims priority of application No. 201841041777 (IN), filed on Nov. 5, 2018.
Prior Publication US 2021/0380557 A1, Dec. 9, 2021
Int. Cl. C07D 401/14 (2006.01)
CPC C07D 401/14 (2013.01) [C07B 2200/13 (2013.01)] 12 Claims
OG exemplary drawing
 
1. Crystalline nilotinib hydrochloride Form L characterized by a powder X-Ray diffraction pattern having at least six peaks selected from 4.9, 5.5, 6.9, 8.9, 9.9, 11, 13.3, 17.8, 19.9, 21.1, 21.5, 22.9, 26.6, 27.6, 28.7, and 29.5° 2θ, where all the peak values listed are ±0.2° 2θ.